<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-six patients with follicular small-cleaved <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FSCL) and 16 patients with follicular mixed <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FML) were treated at the Nichidai Itabashi Hospital between 1981 and 1995 </plain></SENT>
<SENT sid="1" pm="."><plain>The 5-year overall survival rate was 74.3% and 70.0% for the FSCL and FML patients, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>Of the patients with stage III-IV FSCL, 9 were assigned to a "watchful waiting" follow-up course and 13 were treated with a single <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> or CHOP therapy </plain></SENT>
<SENT sid="3" pm="."><plain>The 5-year failure-free survival rate was 66.7% and 33.0%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Of the patients with stage II-IV FML, 6 were treated with CHOP or MACOP-B protocol </plain></SENT>
<SENT sid="5" pm="."><plain>The complete response rate for this group was only 33.3%, and none of the patients were in remission for more than 2 years </plain></SENT>
<SENT sid="6" pm="."><plain>Histological transformation into diffuse aggressive <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was observed in 7 patients, with the median time from diagnosis to transformation at 50 months </plain></SENT>
<SENT sid="7" pm="."><plain>Three of those patients were successfully treated with intensive chemotherapy after transformation </plain></SENT>
</text></document>